AbbVie Inc. (ABBV) Q3 2026 (USD): Adj. EPS 3.82 (exp. 3.73), Revenue 17.4bln (exp. 17.3bln)
ORIGINAL · NewsquawkAbbVie Inc. (ABBV) Q3 2026 (USD): Adj. EPS 3.82 (exp. 3.73), Revenue 17.4bln (exp. 17.3bln)Read originalHide original
Announced 2027 dividend increase of 5.2%, beginning with the dividend payable in February 2027. Adj. gross margin 85.1%. Global Skyrizi revenue 5.776bln. Global Rinvoq revenue 2.706bln. Global Humira revenue 683mln. FY outlook Adj. EPS 13.95-13.99 (exp. 13.91); includes 0.69/shr unfavorable impact from acquired IPR&D and milestones expense YTD through Q3.
AbbVie reported Q3 adjusted EPS and revenue above expectations, announced a 5.2% 2027 dividend increase, and provided FY adjusted EPS guidance with a stated expense impact.
News detail
Announced 2027 dividend increase of 5.2%, beginning with the dividend payable in February 2027. Adj. gross margin 85.1%. Global Skyrizi revenue 5.776bln. Global Rinvoq revenue 2.706bln. Global Humira revenue 683mln. FY outlook Adj. EPS 13.95-13.99 (exp. 13.91); includes 0.69/shr unfavorable impact from acquired IPR&D and milestones expense YTD through Q3.
Related stocks
1 stocks
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.